Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Communication is Key: Ensuring Pregnancy Prevention/Safe Planning in Patients of Reproductive Potential

Premiere Date: Friday, October 21, 2022

This activity offers CE credit for:

1. ABIM (MOC)
2. Family Physicians (AAFP)
3. Medicine (accme)
4. Nursing (ANCC)
5. Pharmacy (acpe)
6. PA (aapa)
7. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Saturday, October 21, 2023
Note: Credit Is No Longer Available

Faculty

Steven Gabardi, PharmD, BCPS, FAST, FCCP (Moderator) Abdominal Organ Transplant Clinical Specialist Brigham and Women's Hospital Assistant Professor of Medicine Harvard Medical School Boston, MA

Michael Wu, MD, RhMSUS  Assistant Professor of Medicine Baylor College of Medicine Houston, TX

Statement of Need

Approximately 45% of pregnancies within utero mycophenolate exposure result in first trimester pregnancy loss and 20% of live births have congenital anomalies.1 Given the well-known embryofetal toxicity associated with mycophenolate treatment and pregnancy, it is imperative that physicians and other health care providers (HCPs) are able to provide accurate and clear counseling on appropriate pregnancy preventive measures for their patients of reproductive potential, as well as potential alternative immunosuppressant regimens. Adequate pregnancy prevention measures for mycophenolate-treated patients include tubal sterilization, intrauterine devices (IUDs), hormonal contraceptives plus one barrier method, or two barrier methods. HCPs also must be comfortable counseling patients on the importance of emergency contraception if appropriate contraceptive measures were either not utilized or experienced failure.

In part two of this REMS CME Outfitters Snack series, host/moderator Dr. Steven Gabardi is joined by Dr. Michael Wu to share strategies for counseling patients of reproductive potential about the risks of pregnancy while taking mycophenolate. Recommendations on necessary contraceptive measures and potential immunosuppressant alternatives to mycophenolate are also discussed.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Counsel patients of reproductive potential on pregnancy prevention and/or planning during mycophenolate treatment, including contraception and alternative immunosuppressant therapies.

Financial Support

This activity is supported by an independent educational grant from the Mycophenolate REMS Group. This activity is intended to be fully compliant with the Mycophenolate REMS education requirements issued by the U.S. Food and Drug Administration (FDA).

Target Audience

Primary care physicians, PAs, NPs, nurses, pharmacists, and physicians specializing in transplant medicine, OB/GYN, surgery, rheumatology, immunology and cardiology

Credit Information

AAFP Credit (Family Physicians):
AAFP:
The AAFP has reviewed Communication is Key: Ensuring Pregnancy Prevention/Safe Planning in Patients of Reproductive Potential and deemed it acceptable for up to 0.50 Enduring Materials, Self-Study AAFP Prescribed credits. Term of Approval is from 10/11/2022 to 10/21/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Gibardi reports no financial relationships to disclose.

Dr. Wu reports the following financial relationships:

Consultant: Musculo, Inc. (Rheumatology Advisor)

Stock Shareholder (direct purchased): AbbVie Inc. (ABBV)

Other Financial or Material Support: Boston University School of Medicine (BUSM); Potomac Center for Medical Education; and Rockpointe Corporation

The following peer reviewer and CME Outfitters staff have no financial relationships:

Thomas Heinrich, MD (peer reviewer)

Morgan Stockberger, MD (planning committee)

Warren Beckman (planning committee)

Susan H. Yarbrough, CHCP (planning committee)

Sandra Caballero, PharmD (planning committee)

Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).